The drug, known as camizestrant, was authorised in an accelerated approval process and can be used in combination with other cancer medicines in patients who have a genetically-driven form of metastatic breast cancer.
Market Samachar is a news aggregator. This article was originally published by NDTV Profit - Latest. Tap the button above to read the full story on their site.